Prompt therapy reduces the duration of systemic corticosteroids in Vogt-Koyanagi-Harada disease

Horie, Yukihiro; Ohno, Shigeaki

doi:10.1007/s00417-008-0869-5

Cited by 18 publications

(11 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Prompt therapy reduces the time period that systemic corticosteroids are needed. 30 Vitiligo is a late manifestation of VKH disease, and the frequency of vitiligo in Japanese VKH disease patients is approximately 20%. 29 Considering the data relating to vitiligo, it is important to compare the SNPs analyses around the NLRP1 gene of VKH disease patients with and without skin lesions.…”

Section: Discussionmentioning

confidence: 99%

“…As we previously reported, prompt systemic corticosteroid therapy can successfully cure VKH disease with few side effects. 30,31 Since the patients are treated with high-dose corticosteroids early on at our clinic, few patients with late manifestations of VKH disease (alopecia, poliosis, and vitiligo) were enrolled in the present study. Thus, it remains unclear whether the SNPs around the NLRP1 gene are associated with the skin lesions of VKH disease.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of NLRP1 gene polymorphisms in Vogt-Koyanagi-Harada disease

et al. 2011

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Evaluation of NLRP1 gene polymorphisms in Vogt-Koyanagi-Harada disease

et al. 2011

Self Cite

View full text Add to dashboard Cite

show abstract

“…Endothelial MIF expression is up-regulated in acute inflammatory pathologies including eczema (29), allergic contact dermatitis (44) and atopic dermatitis (AD) (45). In AD sufferers, epidermal (46), lachrymal fluid (47) and serum (46,48) MIF levels are increased, as is the secretion of MIF by peripheral blood mononuclear cells (PBMCs) (48). Of note, serum MIF is markedly decreased in AD patients who respond positively to steroid treatment (46), while it has recently been shown that symptoms in a murine AD model are ameliorated by treatment with a MIF-DNA vaccine (49).…”

Section: Mif and Cutaneous Pathologiesmentioning

confidence: 99%

MIF: a key player in cutaneous biology and wound healing

Gilliver

Emmerson

Bernhagen

et al. 2010

Experimental Dermatology

View full text Add to dashboard Cite

Owing to its implication in a range of pathological conditions, including asthma, rheumatoid arthritis, atherosclerosis, inflammatory bowel disease and cancer, the pleiotropic cytokine macrophage migration inhibitory factor (MIF) has been the subject of intensive recent investigation. In the field of dermatology, MIF is believed to be a detrimental factor in diseases such as systemic sclerosis, atopic dermatitis, psoriasis, eczema and UV radiation damage. However, its contribution to other aspects of cutaneous biology is currently unclear. Although its expression in intact skin is well characterized, little is known about MIF's role in cutaneous homoeostasis. However, recent data do identify MIF as a key player in the immune privilege of hair follicles. Similarly, although MIF is rapidly released and its local expression significantly induced upon wounding, its primary role in the ensuing repair process remains a source of contention. MIF has been identified as being a key effector of the beneficial effects of estrogen on wound repair, yet studies employing Mif null mice, recombinant MIF, and neutralizing anti-MIF antibodies have failed to provide a consensus as to whether it benefits or inhibits healing. In fact MIF appears to be able to exert both positive and negative effects, with the cell-specific relevancy of MIF in wound healing still unclear. Thus, if MIF and ⁄ or its downstream targets are to be therapeutically useful in the context of cutaneous repair, more needs to be done to establish the nature and mechanism of action of MIF and its receptors in healing wounds.

show abstract

“…However, the rate of taper and duration of treatment remain uncertain. Studies have shown that immunosuppressants need to be maintained for at least 6–9 months and tapered off slowly 1 2 7 8. To date, the duration and rate of taper of immunosuppressants have been based on clinical assessment of disease activity.…”

Section: Introductionmentioning

confidence: 99%